Baiying qingmai formulation ameliorates thromboangiitis obliterans by inhibiting HMGB1/RAGE/NF-κB signaling pathways
Baiying Qingmai Formulation (BF) is a classical clinical prescription used for decades to treat thromboangiitis obliterans (TAO). Although it effectively relieves pain and ischemic ulcers in patients with TAO, its anti-TAO mechanisms remain unclear. The chemical components of BF were analyzed using...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-10-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2022.1018438/full |
_version_ | 1817984515342073856 |
---|---|
author | Chongchong Zou Chongchong Zou Li Liu Chuanqi Huang Song Hu Song Hu |
author_facet | Chongchong Zou Chongchong Zou Li Liu Chuanqi Huang Song Hu Song Hu |
author_sort | Chongchong Zou |
collection | DOAJ |
description | Baiying Qingmai Formulation (BF) is a classical clinical prescription used for decades to treat thromboangiitis obliterans (TAO). Although it effectively relieves pain and ischemic ulcers in patients with TAO, its anti-TAO mechanisms remain unclear. The chemical components of BF were analyzed using high-performance liquid chromatography and the potential targets of the compounds identified in BF were analyzed using molecular docking. Further, the signaling pathways and molecular mechanism of BF in treating TAO were studied using a rat model of TAO. Seven compounds (gallic acid, catechin, chlorogenic acid, caffeic acid, paeoniflorin, quercetin, and paeonol) were identified in BF, and molecular docking predicted their high affinities with HMGB1/RAGE/NF-κB proteins. In in vivo studies, BF not only inhibited the protein expression of HMGB1, RAGE, ICAM-1, and VCAM-1; mRNA levels of HMGB1 and RAGE; and the phosphorylation of NF-κB, ERK, Janus kinase (JNK) and p38 MAPK in the femoral artery, but also reduced the levels of inflammatory cytokines (IL-6, TNF-α, IL-1β, HMGB1) and stable metabolite (TXB2) of cytokine promoting thrombosis (TXA2) in the plasma. Moreover, BF stimulated the secretion of stable metabolite (6-keto-PGF1α) of cytokine inhibiting thrombosis (PGI2) in the plasma. BF inhibited the inflammatory response and thrombosis in the femoral artery, thus reducing the degree of vascular occlusion, which alleviated the symptoms in rats with TAO. Our findings suggest that BF ameliorates TAO by inhibiting the activation of the ERK, JNK, p38 MAPK and HMGB1/RAGE/NF-κB signaling pathways, thereby providing novel ideas for the treatment of TAO and essential information for the further development and utilization of BF as a promising drug to treat TAO. |
first_indexed | 2024-04-13T23:45:42Z |
format | Article |
id | doaj.art-d2c37b332a4945b9a6654afda50115cb |
institution | Directory Open Access Journal |
issn | 1663-9812 |
language | English |
last_indexed | 2024-04-13T23:45:42Z |
publishDate | 2022-10-01 |
publisher | Frontiers Media S.A. |
record_format | Article |
series | Frontiers in Pharmacology |
spelling | doaj.art-d2c37b332a4945b9a6654afda50115cb2022-12-22T02:24:20ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122022-10-011310.3389/fphar.2022.10184381018438Baiying qingmai formulation ameliorates thromboangiitis obliterans by inhibiting HMGB1/RAGE/NF-κB signaling pathwaysChongchong Zou0Chongchong Zou1Li Liu2Chuanqi Huang3Song Hu4Song Hu5Department of Pharmacy, Wuhan Hospital of Traditional Chinese and Western Medicine, Wuhan, ChinaDepartment of Pharmacy, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, ChinaSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, ChinaDepartment of Pharmacy, Wuhan Hospital of Traditional Chinese and Western Medicine, Wuhan, ChinaDepartment of Pharmacy, Wuhan Hospital of Traditional Chinese and Western Medicine, Wuhan, ChinaSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan, ChinaBaiying Qingmai Formulation (BF) is a classical clinical prescription used for decades to treat thromboangiitis obliterans (TAO). Although it effectively relieves pain and ischemic ulcers in patients with TAO, its anti-TAO mechanisms remain unclear. The chemical components of BF were analyzed using high-performance liquid chromatography and the potential targets of the compounds identified in BF were analyzed using molecular docking. Further, the signaling pathways and molecular mechanism of BF in treating TAO were studied using a rat model of TAO. Seven compounds (gallic acid, catechin, chlorogenic acid, caffeic acid, paeoniflorin, quercetin, and paeonol) were identified in BF, and molecular docking predicted their high affinities with HMGB1/RAGE/NF-κB proteins. In in vivo studies, BF not only inhibited the protein expression of HMGB1, RAGE, ICAM-1, and VCAM-1; mRNA levels of HMGB1 and RAGE; and the phosphorylation of NF-κB, ERK, Janus kinase (JNK) and p38 MAPK in the femoral artery, but also reduced the levels of inflammatory cytokines (IL-6, TNF-α, IL-1β, HMGB1) and stable metabolite (TXB2) of cytokine promoting thrombosis (TXA2) in the plasma. Moreover, BF stimulated the secretion of stable metabolite (6-keto-PGF1α) of cytokine inhibiting thrombosis (PGI2) in the plasma. BF inhibited the inflammatory response and thrombosis in the femoral artery, thus reducing the degree of vascular occlusion, which alleviated the symptoms in rats with TAO. Our findings suggest that BF ameliorates TAO by inhibiting the activation of the ERK, JNK, p38 MAPK and HMGB1/RAGE/NF-κB signaling pathways, thereby providing novel ideas for the treatment of TAO and essential information for the further development and utilization of BF as a promising drug to treat TAO.https://www.frontiersin.org/articles/10.3389/fphar.2022.1018438/fullthromboangiitis obliteransBuerger’s diseaseinflammationtraditional Chinese medicinesolanum lyratum |
spellingShingle | Chongchong Zou Chongchong Zou Li Liu Chuanqi Huang Song Hu Song Hu Baiying qingmai formulation ameliorates thromboangiitis obliterans by inhibiting HMGB1/RAGE/NF-κB signaling pathways Frontiers in Pharmacology thromboangiitis obliterans Buerger’s disease inflammation traditional Chinese medicine solanum lyratum |
title | Baiying qingmai formulation ameliorates thromboangiitis obliterans by inhibiting HMGB1/RAGE/NF-κB signaling pathways |
title_full | Baiying qingmai formulation ameliorates thromboangiitis obliterans by inhibiting HMGB1/RAGE/NF-κB signaling pathways |
title_fullStr | Baiying qingmai formulation ameliorates thromboangiitis obliterans by inhibiting HMGB1/RAGE/NF-κB signaling pathways |
title_full_unstemmed | Baiying qingmai formulation ameliorates thromboangiitis obliterans by inhibiting HMGB1/RAGE/NF-κB signaling pathways |
title_short | Baiying qingmai formulation ameliorates thromboangiitis obliterans by inhibiting HMGB1/RAGE/NF-κB signaling pathways |
title_sort | baiying qingmai formulation ameliorates thromboangiitis obliterans by inhibiting hmgb1 rage nf κb signaling pathways |
topic | thromboangiitis obliterans Buerger’s disease inflammation traditional Chinese medicine solanum lyratum |
url | https://www.frontiersin.org/articles/10.3389/fphar.2022.1018438/full |
work_keys_str_mv | AT chongchongzou baiyingqingmaiformulationamelioratesthromboangiitisobliteransbyinhibitinghmgb1ragenfkbsignalingpathways AT chongchongzou baiyingqingmaiformulationamelioratesthromboangiitisobliteransbyinhibitinghmgb1ragenfkbsignalingpathways AT liliu baiyingqingmaiformulationamelioratesthromboangiitisobliteransbyinhibitinghmgb1ragenfkbsignalingpathways AT chuanqihuang baiyingqingmaiformulationamelioratesthromboangiitisobliteransbyinhibitinghmgb1ragenfkbsignalingpathways AT songhu baiyingqingmaiformulationamelioratesthromboangiitisobliteransbyinhibitinghmgb1ragenfkbsignalingpathways AT songhu baiyingqingmaiformulationamelioratesthromboangiitisobliteransbyinhibitinghmgb1ragenfkbsignalingpathways |